18F-DCFBC

DRACPC ID  DRACPC0054

Active Ingredients   18F-DCFBC

Description  A radioconjugate containing a low molecular weight tracer, DCFBC, specific for prostate-specific membrane antigen (PSMA) and labeled with the positron-emitting isotope fluorine F 18 with potential prostate tumor imaging upon positron emission tomography (PET). Upon administration, the DCFBC moiety of fluorine F 18 DCFBC specifically targets and binds to the tumor associated antigen PSMA, thereby allowing the visualization of tumor cells expressing PSMA upon PET. PSMA is a transmembrane glycoprotein highly expressed on malignant prostate epithelial cells and vascular endothelial cells of various solid tumors.

Synonyms  DCFBC F-18; Fluorine F 18 DCFBC; [18]F-DCFBC;N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine; 18F-DCFBC

Type  Small Molecule

Disease  Prostatet cancer

Classification

  

Peptide and derivative Cancer targeted Radioconjugates

Structure Information


Molecular Formula  C16H19FN2O7S

Molecular Weight  401.4

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (2S)-2-[[(1R)-1-carboxy-2-[(4-(18F)fluoranylphenyl)methylsulfanyl]ethyl]carbamoylamino]pentanedioic acid

InChI  InChI=1S/C16H19FN2O7S/c17-10-3-1-9(2-4-10)7-27-8-12(15(24)25)19-16(26)18-11(14(22)23)5-6-13(20)21/h1-4,11-12H,5-8H2,(H,20,21)(H,22,23)(H,24,25)(H2,18,19,26)/t11-,12-/m0/s1/i17-1

InChI_Key IDTMSHGCAZPVLC-STUNTBJNSA-N

SMILES  O=C(CC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CSCC1=CC=C(C=C1)[18F])=O)O

External Codes


PubChem CID  25067411

DrugBank Accession Number  DB14772

NCI Thesaurus Code  C96234  

UNII  TUP7882K8T   GSRS

CAS  1169942-33-9



Drug approval


Drug indication
    Investigated for use/treatment in prostatet cancer.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT01815515 Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer. Metastatic Prostate Cancer Phase 1/2 Diagnostic
NCT01417182 Phase 1 Biodistribution and Pharmacokinetic Study of 18F-DCFBC PSMA Based PET in Patients With Advanced Prostate Cancer Prostate Cancer Phase 1 Screening
NCT02190279 A Pilot Study of 18F-DCFBC PET/CT in Prostate Cancer Prostatic Neoplasms; Prostate Cancer Early Phase 1 Diagnostic
NCT01496157 Evaluation of PSMA-based PET as an Imaging Biomarker of Primary Prostate Cancer Prostate Cancer Phase 1/2 Diagnostic

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.